Search
Penn spin-out Incuta Therapeutics is developing a long-lasting JAK inhibitor for hidradenitis suppurativa that is designed to concentrate at the site of the lesions
CEO Gerri Henwood, who has successfully led numerous biotech companies, describes what about this opportunity excited her, and what is needed to get the program into the clinic.
8 hours ago
.png){kind=logo}